U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Levofloxacin Oral, Injection products
  1. Development Resources

Levofloxacin Oral, Injection products

Exceptions or additions to the recognized standards

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Methicillin-susceptible
Staphylococcus aureus

≤2

4

≥8

≥17

14–16

≤13

S = Susceptible; I = Intermediate; R = Resistant

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Acinetobacter spp.

Stenotrophomonas maltophilia

Other Non-Enterobacterales

Streptococcus spp. Viridans Group

Neisseria meningitidis

Back to Top